• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

The variable penetrance and spectrum of manifestations of multiple endocrine neoplasia type 1.

作者信息

Carty S E, Helm A K, Amico J A, Clarke M R, Foley T P, Watson C G, Mulvihill J J

机构信息

Department of Surgery, University of Pittsburgh School of Medicine, Pa. 15261, USA.

出版信息

Surgery. 1998 Dec;124(6):1106-13; discussion 1113-4. doi: 10.1067/msy.1998.93107.

DOI:10.1067/msy.1998.93107
PMID:9854591
Abstract

BACKGROUND

Some experts maintain that (1) > 90% of patients with multiple endocrine neoplasia type 1 (MEN1) are first seen with hyperparathyroidism (HPTH) so that routine screening for other features is unnecessary and (2) MEN1 has > or = 94% penetrance by age 50 years.

METHODS

We constructed a regional registry of patients with or at risk for MEN1 and examined phenotypic profiles in 34 patients. MEN1 was defined as (1) endocrinopathy of 2 of the 3 principal related tissues (parathyroid, gastrointestinal endocrine, pituitary) or (2) 1 such feature plus a first-degree relative with MEN1.

RESULTS

The initial feature of MEN1 was HPTH in 50%, pituitary tumor in 18%, and gastrointestinal endocrine tumor in 32% of patients, with overall incidences of 82%, 65%, and 74%, respectively. HPTH developed by age 50 years in 73% of patients and by age 70 years in 83%. Penetrance of MEN1 at age 50 years was 82%. Associated features included renal (1) and rectal (1) cancer, malignant thymic carcinoid (1), and malignant pheochromocytoma (1).

CONCLUSIONS

Expression of MEN1 can vary considerably from established patterns. In our geographic region HPTH does not routinely precede other features of MEN1 and cannot be used to distinguish affected patients among those at risk. MEN1 can be inapparent until late in life and may be significantly underdiagnosed.

摘要

相似文献

1
The variable penetrance and spectrum of manifestations of multiple endocrine neoplasia type 1.
Surgery. 1998 Dec;124(6):1106-13; discussion 1113-4. doi: 10.1067/msy.1998.93107.
2
Age-related penetrance of endocrine tumours in multiple endocrine neoplasia type 1 (MEN1): a multicentre study of 258 gene carriers.1型多发性内分泌肿瘤(MEN1)中内分泌肿瘤的年龄相关外显率:一项对258名基因携带者的多中心研究。
Clin Endocrinol (Oxf). 2007 Oct;67(4):613-22. doi: 10.1111/j.1365-2265.2007.02934.x. Epub 2007 Jun 21.
3
Diagnosis and treatment of multiple endocrine neoplasia type 1 (MEN1).1型多发性内分泌腺瘤病(MEN1)的诊断与治疗。
Minerva Endocrinol. 2013 Mar;38(1):17-28.
4
[Multiple Endocrine Neoplasia I (Wermers Syndrome), Forms of Clinical Manifestation, 5 Case Studies].[多发性内分泌腺瘤病I型(韦默斯综合征),临床表现形式,5例病例研究]
Vnitr Lek. 2016 Fall;62(9 Suppl 3):140-149.
5
Causes of death and prognostic factors in multiple endocrine neoplasia type 1: a prospective study: comparison of 106 MEN1/Zollinger-Ellison syndrome patients with 1613 literature MEN1 patients with or without pancreatic endocrine tumors.1型多发性内分泌腺瘤病的死亡原因及预后因素:一项前瞻性研究:106例MEN1/卓艾综合征患者与1613例有或无胰腺内分泌肿瘤的文献报道的MEN1患者的比较
Medicine (Baltimore). 2013 May;92(3):135-181. doi: 10.1097/MD.0b013e3182954af1.
6
Multiple endocrine neoplasia type 1.1型多发性内分泌腺瘤病
Orphanet J Rare Dis. 2006 Oct 2;1:38. doi: 10.1186/1750-1172-1-38.
7
Acromegaly in a multiple endocrine neoplasia type 1 (MEN1) family with low penetrance of the disease.1型多发性内分泌腺瘤病(MEN1)家族中具有低疾病外显率的肢端肥大症。
Eur J Endocrinol. 2005 Dec;153(6):741-6. doi: 10.1530/eje.1.02022.
8
Multiple endocrine neoplasia type 1: extensive analysis of a large database of Florentine patients.多发性内分泌腺瘤病 1 型:对佛罗伦萨患者大型数据库的广泛分析。
Orphanet J Rare Dis. 2018 Nov 14;13(1):205. doi: 10.1186/s13023-018-0938-8.
9
Clinical studies of multiple endocrine neoplasia type 1 (MEN1).1型多发性内分泌腺瘤病(MEN1)的临床研究。
QJM. 1996 Sep;89(9):653-69. doi: 10.1093/qjmed/89.9.653.
10
Understanding the clinical course of genotype-negative MEN1 patients can inform management strategies.了解基因型阴性 MEN1 患者的临床病程有助于制定管理策略。
Surgery. 2021 Jan;169(1):175-184. doi: 10.1016/j.surg.2020.04.067. Epub 2020 Jul 20.

引用本文的文献

1
Cutaneous lesions and other non-endocrine manifestations of Multiple Endocrine Neoplasia type 1 syndrome.多发性内分泌腺瘤病 1 型综合征的皮肤损害及其他非内分泌表现。
Front Endocrinol (Lausanne). 2023 Jul 7;14:1191040. doi: 10.3389/fendo.2023.1191040. eCollection 2023.
2
Beyond the "3 Ps": A critical appraisal of the non-endocrine manifestations of multiple endocrine neoplasia type 1.超越“3P”:对 1 型多发性内分泌肿瘤非内分泌表现的批判性评估。
Front Endocrinol (Lausanne). 2022 Oct 17;13:1029041. doi: 10.3389/fendo.2022.1029041. eCollection 2022.
3
Less Than Subtotal Parathyroidectomy for Multiple Endocrine Neoplasia Type 1 Primary Hyperparathyroidism: A Systematic Review and Meta-Analysis.
对于多发性内分泌肿瘤 1 型原发性甲状旁腺功能亢进症,行次全甲状旁腺切除术与全甲状旁腺切除术的疗效比较:系统评价和荟萃分析。
World J Surg. 2022 Nov;46(11):2666-2675. doi: 10.1007/s00268-022-06633-7. Epub 2022 Jun 29.
4
Pancreaticoduodenectomy Is the Best Surgical Procedure for Zollinger-Ellison Syndrome Associated with Multiple Endocrine Neoplasia Type 1.胰十二指肠切除术是治疗与1型多发性内分泌腺瘤相关的佐林格-埃利森综合征的最佳手术方法。
Cancers (Basel). 2022 Apr 11;14(8):1928. doi: 10.3390/cancers14081928.
5
Multiple endocrine neoplasia type 1 in patients with gastroenteropancreatic neuroendocrine tumors: An opportunity for early diagnosis and appropriate management.胃肠胰神经内分泌肿瘤患者的1型多发性内分泌肿瘤:早期诊断和适当管理的契机。
Mol Clin Oncol. 2020 Sep;13(3):4. doi: 10.3892/mco.2020.2074. Epub 2020 Jun 18.
6
18F-FDOPA PET/CT accurately identifies MEN1-associated pheochromocytoma.18F-氟多巴正电子发射断层扫描/计算机断层扫描(18F-FDOPA PET/CT)能准确识别与多发性内分泌腺瘤1型(MEN1)相关的嗜铬细胞瘤。
Endocrinol Diabetes Metab Case Rep. 2020 Mar 3;2020. doi: 10.1530/EDM-19-0156.
7
Pheochromocytomas and Paragangliomas: New Developments with Regard to Classification, Genetics, and Cell of Origin.嗜铬细胞瘤和副神经节瘤:关于分类、遗传学及起源细胞的新进展
Cancers (Basel). 2019 Jul 29;11(8):1070. doi: 10.3390/cancers11081070.
8
Recommendation of long-term and systemic management according to the risk factors in rectal NETs patients.推荐根据直肠 NET 患者的风险因素进行长期和系统的管理。
Sci Rep. 2019 Feb 20;9(1):2404. doi: 10.1038/s41598-018-37707-z.
9
Chemoprevention with Somatuline© Delays the Progression of Pancreatic Neuroendocrine Neoplasms in a Mouse Model of Multiple Endocrine Neoplasia Type 1 (MEN1).使用索马杜林®进行化学预防可延缓1型多发性内分泌腺瘤病(MEN1)小鼠模型中胰腺神经内分泌肿瘤的进展。
World J Surg. 2019 Mar;43(3):831-838. doi: 10.1007/s00268-018-4839-8.
10
High prevalence of chronic kidney disease in patients with multiple endocrine neoplasia type 1 and improved kidney function after parathyroidectomy.多发性内分泌肿瘤 1 型患者中慢性肾脏病的高患病率和甲状旁腺切除术后肾功能的改善。
Surgery. 2019 Jan;165(1):124-128. doi: 10.1016/j.surg.2018.04.064. Epub 2018 Nov 7.